Hims & Hers Stock Soars on Strategic Pact with Novo Nordisk
Published on 03/11/2026 at 00:48 | Redaktion boerse-global.de
A single-day surge of 40% is an extraordinary event, even in the volatile telehealth sector. Shares of Hims & Hers Health experienced precisely that following the announcement of a landmark cooperation agreement with Danish pharmaceutical giant Novo Nordisk. The deal simultaneously resolves an ongoing patent dispute, removing a significant overhang that had weighed on the stock.
A Pivot in Strategy for Weight-Loss Medications
The core of the new agreement centers on distribution. Hims & Hers will now offer Novo Nordisk's branded weight-loss medications, Ozempic and Wegovy—both based on the active ingredient semaglutide—through its digital platform. In exchange, the company will cease actively marketing its own compounded GLP-1 preparations. Existing patients on those therapies are to be transitioned to the approved brand-name drugs, where clinically appropriate.
This partnership follows a turbulent history between the two firms. A previous collaboration dissolved after just a few months when Hims & Hers continued to market lower-cost alternative products. At the time, Novo Nordisk criticized a Hims-specific Wegovy formulation as an "unapproved, counterfeit, and untested copy." Hims & Hers withdrew that product two days after intervention by the U.S. Food and Drug Administration (FDA). The new pact represents a second attempt, this time with explicit contractual limitations for the telehealth provider.
Strong Fundamentals Underpin the Move
This strategic shift comes as Hims & Hers reports robust underlying growth. For fiscal year 2025, the company generated revenue of $2.35 billion, representing a 59% year-over-year increase. Its subscriber base surpassed 2.5 million users, supported by a gross margin of 73.8%. International operations expanded by approximately 400%, and management has set a target to achieve over $1 billion in annual international revenue within three years.
Analysts Revise Targets Upward
The market's reaction was immediate and decisive. On Monday, the stock closed at $22.15, marking a 40.7% gain. Trading volume reached 168.1 million shares—roughly 557% above the three-month average. In the subsequent session, the equity advanced a further 5.9% to $23.47.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Several financial institutions responded by raising their price targets. Needham increased its target to $30, while Deutsche Bank set a $28 target alongside a "Hold" rating. Citi established a $24 objective. Bank of America upgraded the stock from "Underperform" to "Neutral," citing the elimination of litigation risk as a key rationale. BMO Capital Markets also noted that the agreement addresses a primary obstacle to growth.
Future Hinges on Successful Patient Transitions
Despite the recent powerful rally, the share price remains approximately 62% below its 52-week high of $70.43. The critical factor for future performance will be the company's ability to migrate a meaningful portion of its subscriber base to the higher-priced branded medications. The scale of this transition will directly influence the future evolution of both revenue mix and profitability margins for Hims & Hers.
Ad
Hims & Hers Stock: New Analysis - 11 March
Fresh Hims & Hers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
